CaudatinCAS# 38395-02-7 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 38395-02-7 | SDF | Download SDF |
| PubChem ID | 72948694 | Appearance | White powder |
| Formula | C28H42O7 | M.Wt | 490.6 |
| Type of Compound | Steroids | Storage | Desiccate at -20°C |
| Solubility | Soluble in methan | ||
| Chemical Name | [(3S,8S,9R,10R,12R,13S,14R,17R)-17-acetyl-3,8,14,17-tetrahydroxy-10,13-dimethyl-1,2,3,4,7,9,11,12,15,16-decahydrocyclopenta[a]phenanthren-12-yl] (E)-3,4-dimethylpent-2-enoate | ||
| SMILES | CC(C)C(=CC(=O)OC1CC2C3(CCC(CC3=CCC2(C4(C1(C(CC4)(C(=O)C)O)C)O)O)O)C)C | ||
| Standard InChIKey | VWLXIXALPNYWFH-UBHIOMQOSA-N | ||
| Standard InChI | InChI=1S/C28H42O7/c1-16(2)17(3)13-23(31)35-22-15-21-24(5)9-8-20(30)14-19(24)7-10-27(21,33)28(34)12-11-26(32,18(4)29)25(22,28)6/h7,13,16,20-22,30,32-34H,8-12,14-15H2,1-6H3/b17-13+/t20-,21+,22+,24-,25+,26-,27-,28+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Caudatin exerts antiproliferative effects on human hepatocellular carcinoma SMMC7721 cells. 2. Caudatin has anticancer activity, due partly to its inhibition of cell proliferation and induction of apoptosis in cancer cells through caspase activation. 3. Caudatin exhibits significantly inhibitory activity against HBV DNA replication with IC50 values in the range of 2.82-7.48 μM. 4. Caudatin inhibits carcinomic human alveolar basal epithelial cell growth and angiogenesis by targeting GSK3β/β-catenin pathway and suppressing VEGF production. |
| Targets | VEGFR | GSK-3 | HBV |
Caudatin Dilution Calculator
Caudatin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.0383 mL | 10.1916 mL | 20.3832 mL | 40.7664 mL | 50.958 mL |
| 5 mM | 0.4077 mL | 2.0383 mL | 4.0766 mL | 8.1533 mL | 10.1916 mL |
| 10 mM | 0.2038 mL | 1.0192 mL | 2.0383 mL | 4.0766 mL | 5.0958 mL |
| 50 mM | 0.0408 mL | 0.2038 mL | 0.4077 mL | 0.8153 mL | 1.0192 mL |
| 100 mM | 0.0204 mL | 0.1019 mL | 0.2038 mL | 0.4077 mL | 0.5096 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- NSC 663284
Catalog No.:BCC7199
CAS No.:383907-43-5
- 3',4'-Anhydrovinblastine
Catalog No.:BCN2392
CAS No.:38390-45-3
- Taxinine
Catalog No.:BCN6944
CAS No.:3835-52-7
- Neuropeptide W-23 (human)
Catalog No.:BCC5961
CAS No.:383415-79-0
- UC 112
Catalog No.:BCC8042
CAS No.:383392-66-3
- Homovanillic Acid Sulfate
Catalog No.:BCN2226
CAS No.:38339-06-9
- 3-O-beta-D-Glucopyranosylplatycodigenin
Catalog No.:BCN7832
CAS No.:38337-25-6
- YE 120
Catalog No.:BCC6188
CAS No.:383124-82-1
- Minoxidil
Catalog No.:BCC4297
CAS No.:38304-91-5
- Naringenin trimethyl ether
Catalog No.:BCN5437
CAS No.:38302-15-7
- Burchellin
Catalog No.:BCN6676
CAS No.:38276-59-4
- Glucose-conjugated MGMT inhibitor
Catalog No.:BCC1597
CAS No.:382607-78-5
- Ganaxolone
Catalog No.:BCC7397
CAS No.:38398-32-2
- Aloenin
Catalog No.:BCN8438
CAS No.:38412-46-3
- Altechromone A
Catalog No.:BCN7422
CAS No.:38412-47-4
- 3,4,4',7-Tetrahydroxyflavan
Catalog No.:BCN5438
CAS No.:38412-82-7
- Sclareol glycol
Catalog No.:BCN7007
CAS No.:38419-75-9
- H-Lys-OEt .2HCl
Catalog No.:BCC2980
CAS No.:3844-53-9
- Asatone
Catalog No.:BCN7761
CAS No.:38451-63-7
- Deacetyleupaserrin
Catalog No.:BCN7228
CAS No.:38456-39-2
- Eucannabinolide
Catalog No.:BCN7221
CAS No.:38458-58-1
- Crotafoline
Catalog No.:BCN2075
CAS No.:38494-87-0
- Tarafenacin
Catalog No.:BCC4147
CAS No.:385367-47-5
- Daphnicyclidin D
Catalog No.:BCN7081
CAS No.:385384-24-7
Caudatin inhibits carcinomic human alveolar basal epithelial cell growth and angiogenesis through modulating GSK3beta/beta-catenin pathway.[Pubmed:22678744]
J Cell Biochem. 2012 Nov;113(11):3403-10.
In this study, we investigate the anti-cancer activity of Caudatin in carcinomic human alveolar basal epithelial cell line A549 and anti-angiogenic activity in human umbilical vein endothelial cells (HUVECs). We show that Caudatin impairs the cell viability and induces G(0) /G(1) phase arrest in A549 cells with a dose dependent manner. A549 cells, not HUVECs, dealing with Caudatin exhibited typical characteristics of apoptosis, which were accompanied by activation of caspase-3, caspase-9 and Poly(ADP-Ribose) Polymerase (PARP). In addition, Caudatin treatment resulted in a decrease of beta-catenin and increase of phosphorylation of beta-catenin, and inhibited phosphorylation levels of GSK3beta (Ser 9) in A549 cells. Conditional medium of A549 cells-induced or growth factors-induced tube formation of HUVECs was markedly inhibited by Caudatin treatment, which was associated with the inhibiting VEGF secretion from A549 cells by Caudatin. Our findings suggest that Caudatin inhibits carcinomic human alveolar basal epithelial cell growth and angiogenesis by targeting GSK3beta/beta-catenin pathway and suppressing VEGF production.
Design, synthesis and biological evaluation of caudatin analogs as potent hepatitis B virus inhibitors.[Pubmed:25181984]
Med Chem. 2015;11(2):165-79.
Thirty-nine Caudatin analogs were designed and synthesized. Their anti-hepatitis B virus (HBV) activities were evaluated in vitro. Among them, twenty-three compounds showed much better anti-HBV activity than Caudatin, and eleven compounds significantly inhibited the HBV DNA replication with IC50 values < 10 muM. Interestingly, three compounds (22, 28, 29) exhibited excellent activity against the secretion of HBsAg (IC50 = 63.02 muM, 52.81 muM, 56.08 muM), HBeAg (IC50 = 204.80 muM, 173.51 muM, 70.39 muM), along with HBV DNA replication (IC50 = 24.55 muM, 5.69 muM, 8.23 muM) with lower cytotoxicity. The structure-activity relationships (SARs) of these Caudatin analogs were also discussed.
Caudatin inhibits human hepatoma cell growth and metastasis through modulation of the Wnt/beta-catenin pathway.[Pubmed:24064800]
Oncol Rep. 2013 Dec;30(6):2923-8.
In the present study, we investigated the antitumor activity of Caudatin in the human hepatoma cell line SMMC7721 by analysis of cell viability, cell cycle distribution, apoptosis and metastasis. The results showed that Caudatin impaired the cell viability and inhibited the growth of SMMC-7721 cells in a time- and dose-dependent manner and resulted in cell cycle arrest in the G2 phase. In addition, SMMC-7721 cells, treated with Caudatin exhibited typical characteristics of apoptosis. Furthermore, Caudatin treatment resulted in a decrease in beta-catenin and GSK3beta in SMMC-7721 cells, with a concomitant reduction in metastatic capability and expression of Wnt signaling pathway targeted genes including cox-2, mmp-2 and mmp-9. Our findings revealed that Caudatin inhibits human hepatoma cell growth and metastasis by targeting the GSK3beta/beta-catenin pathway and suppressing VEGF production.
